Vivisum Partners recently published a new series of strategy navigators focusing on the ulcerative colitis outlook. The market analysis encompasses qualitive and quantitative research, including surveys of 126 gastroenterologists.
Why use ulcerative colitis outlook research?
The market for ulcerative colitis drugs is going through some changes. With new ulcerative colitis drugs entering the market, it’s important to have up-to-date market insights to find the most profitable path. This supports the end goal of identifying flaws within your plan, finding growth opportunities, and figuring out strengths.
Identify Flaws in your Brand Strategy
The insights in Vivisum’s ulcerative colitis outlook research allow drug manufacturers to find weaknesses that they may not have realized in the first place. Identifying these flaws gives them an opportunity to improve their customer experience, shift market share in their favor and grow profits.
It could also be the case that a client is outperforming others in some categories but struggling in certain critical areas. By addressing those areas, the drug should perform better in the market.
For example, Vivisum’s ulcerative colitis outlook research found that Upadacitinib lacks in manufacturer support compared to competitors. By addressing this lack of support, the manufacturer can better position the drug to become a top performer in the category. Conversely, drugs that compete with Upadacitinib can benefit from gastroenterologists’ perceptions of its lack of support. By positioning their drugs as having better support, competing manufacturers can capitalize on Upadacitinib’s weakness.
Find Opportunities to Improve Plans
Even if your ulcerative colitis treatment is not included in any industry outlook research, you can find still use that data to find gaps in the marketplace. The various treatments in the ulcerative colitis market each have unique clinical profiles around:
How they perform against those clinical attributes shapes the opportunities available within the ulcerative colitis clinical pipeline.
Evaluating how existing and pipeline drugs score against these six clinical attributes will help identify gaps in the market that your brand could fill. For example, several new ulcerative colitis drugs in the pipeline score low for access. This is an opportunity for both pipeline and inline brands with strong access to differentiate themselves against a new competitor.
Discover Your Strengths
Companies can not test everything about their brands prior to launch, which leads to knowledge gaps. A new drug could be a top performer in a category that is important to health care providers but that may not have been a focus on the brand team’s research. With proper ulcerative colitis outlook research, companies can identify their strengths and allocate more resources to expand in them in an effort to convert more health care providers to prescribe the drug.
Among pipeline drugs, Guselkumab has a distinct advantage in efficacy compared to competitors, according to surveyed gastroenterologists. This will no doubt be a significant component to the brand’s marketing strategy.
Vivisum’s Ulcerative Colitis Clinical Pipeline Analysis is the most comprehensive ulcerative colitis outlook research available. It provides deep analysis of gastroenterologists’ perceptions of ulcerative colitis pipeline therapies, including their familiarity, level of excitement, and expectations compared vs competitor products.